Atezolizumab Plus Chemotherapy vs. Chemotherapy in Advanced or Metastatic Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis
Purpose: The IMpassion130 trial demonstrated the efficacy of adding atezolizumab to paclitaxel for advanced or metastatic triple-negative breast cancer (TNBC). The current study evaluated the cost-effectiveness of adding atezolizumab to nab-paclitaxel for TNBC from the perspective of Chinese health...
Сохранить в:
| Главные авторы: | , , , |
|---|---|
| Формат: | |
| Опубликовано: |
Frontiers Media S.A.,
2021-10-01T00:00:00Z.
|
| Предметы: | |
| Online-ссылка: | Connect to this object online. |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|
Internet
Connect to this object online.3rd Floor Main Library
| Шифр: |
A1234.567 |
|---|---|
| Копировать 1 | Доступно |